Abstract:Background Bipolar depression is the major cause of morbidity in patients with bipolar disorder. It affects psychosocial functioning and markedly impairs occupational productivity. Anhedonia is one of the most debilitating symptoms of depression contributing to treatment resistance. It correlates with suicidality, low quality of life, social withdrawal, and poor treatment response. Currently, there is no approved treatment specifically targeting anhedonia. Emerging evidence suggests that ketamine possesses anti‐anhedonic properties in individuals with depression. Objectives The aim of this naturalistic open‐label study was to investigate the effect of add‐on ketamine treatment on anhedonia in treatment resistant bipolar depression. Methods Our main interest was the change in patient‐reported (Snaith‐Hamilton Pleasure Scale) and rater‐based anhedonia measure (Montgomery–Åsberg Depression Rating Scale‐anhedonia subscale). The secondary aim was to analyze the score change in three Inventory of Depressive Symptomatology‐Self Report (IDS‐SR) domains: mood/cognition, anxiety/somatic, and sleep. Patients underwent assessments at several time points, including baseline, after the third, fifth, and seventh ketamine infusions. Additionally, a follow‐up assessment was conducted 1 week following the final ketamine administration. Results We found improvement in anhedonia symptoms according to both patient‐reported and rater‐based measures. The improvement in IDS‐SR domains was most prominent in anxiety/somatic factor and mood/cognition factor, improvement in sleep factor was not observed. No serious adverse events occurred. Conclusion Add‐on ketamine seems to be a good choice for the treatment of anhedonia in treatment resistant bipolar depression. It also showed a good effect in reducing symptoms of anxiety in this group of patients. Considering unmet needs and the detrimental effect of anhedonia and anxiety, more studies are needed on ketamine treatment in resistant bipolar depression.

Polish standard of treatment with racemic ketamine for patients with depressive disorders developed by a Working Group appointed by the National Consultant in the field of psychiatry

Polish standard of treatment with racemic ketamine for patients with depressive disorders developed by a Working Group appointed by the National Consultant in the field of psychiatry

Magnesium and ketamine in the treatment of depression

Central nervous system-related safety and tolerability of add-on ketamine to standard of care treatment in treatment-resistant psychotic depression in patients with major depressive disorder and bipolar disorder

Around anesthesia: anesthetic aspects of electroconvulsive treatment in the light of the latest reports – review article

Risks Associated with Misuse of Ketamine as a Rapid-Acting Antidepressant

Depression with comorbid borderline personality disorder - could ketamine be a treatment catalyst?

Effect of Ketamine on Sleep in Treatment-Resistant Depression: A Systematic Review

Single arketamine in treatment resistant depression: Presentation of 3 cases with regard to sick-leave duration

The quest for optimal ketamine dosing formula in treatment-resistant major depressive disorder

Efficacy and safety of a 4-week course of repeated subcutaneous ketamine injections for treatment-resistant depression (KADS study): randomised double-blind active-controlled trial

The effectiveness of (R)-ketamine and its mechanism of action differ from those of (S)-ketamine in a chronic unpredictable mild stress model of depression in C57BL/6J mice

The role of glutamatergic modulation in the mechanism of action of ketamine, a prototype rapid-acting antidepressant drug

Ketamine for treatment-resistant major depressive disorder: Double-blind active-controlled crossover study

Ketamine in depression and electroconvulsive therapy

Anhedonia in bipolar depression treated with ketamine

Residual Depressive Symptoms in Treatment-Resistant Bipolar Depression Following Short-Term Ketamine Administration

R-Ketamine: A Rapid-Onset and Sustained Antidepressant Without Psychotomimetic Side Effects

Ketamine, Esketamine, and Arketamine: Their Mechanisms of Action and Applications in the Treatment of Depression and Alleviation of Depressive Symptoms

Key considerations for the use of ketamine and esketamine for the treatment of depression: focusing on administration, safety, and tolerability

[Ketamine as an anesthetic, analgesic and anti-depressant]